miR‑885‑5p suppresses osteosarcoma proliferation, migration and invasion through regulation of β‑catenin

Liu, Yan; Bao, Zili; Tian, Wanqing; Huang, Guojin

doi:10.3892/ol.2018.9768

Cited by 12 publications

(17 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[34] In contrast, miR-885-5p suppressed proliferation, migration and invasion in vitro in osteosarcoma cells, and was downregulated in osteosarcoma patients with low expression levels being associated with a poor prognosis. [35] In our study, miR-885-5p was downregulated in the recurrent tumors, possibly matching the findings in osteosarcoma with low levels of miR-885-5p being associated with more proliferation and a poorer prognosis. Lastly, in our comparison of primary and recurrent WDLPS we did not detect differential expression of the microRNAs that were previously found to be important for sarcomagenesis in WDLPS, such as miR-628 [6], miR-675 [6], miR-26a [8], miR-451 [8] or miR-193b.…”

Section: Discussionsupporting

confidence: 87%

MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma

et al. 2020

View full text Add to dashboard Cite

Approximately one-third of the patients with well-differentiated liposarcoma (WDLPS) will develop a local recurrence. Not much is known about the molecular relationship between the primary tumor and the recurrent tumor, which is important to reveal potential drivers of recurrence. Here we investigated the biology of recurrent WDLPS by comparing paired primary and recurrent WDLPS using microRNA profiling and genome-wide DNA methylation analyses. In total, 27 paired primary and recurrent WDLPS formalin-fixed and paraffinembedded tumor samples were collected. MicroRNA expression profiles were determined using TaqMan ® Low Density Array (TLDA) cards. Genome-wide DNA methylation and differentially methylated regions (DMRs) were assessed by methylated DNA sequencing (MeD-seq). A supervised cluster analysis based on differentially expressed microRNAs between paired primary and recurrent WDLPS did not reveal a clear cluster pattern separating the primary from the recurrent tumors. The clustering was also not based on tumor localization, time to recurrence, age or status of the resection margins. Changes in DNA methylation between primary and recurrent tumors were extremely variable, and no consistent DNA methylation changes were found. As a result, a supervised clustering analysis based on DMRs between primary and recurrent tumors did not show a distinct cluster pattern based on any of the features. Subgroup analysis for tumors localized in the extremity or the retroperitoneum also did not yield a clear distinction between primary and recurrent WDLPS samples. In conclusion, microRNA expression profiles and DNA methylation profiles do not distinguish between primary and recurrent WDLPS and no putative common drivers could be identified.

show abstract

Section: Discussionsupporting

confidence: 87%

MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…2,3 The carcinogenesis and tumor progression of thyroid cancer result from varieties of factors, including variation of gene expression and changing activity in signaling pathways. 4,5 Dysregulation of miRNAs has been documented to be implicated in a number of cancers, 8,9 including thyroid cancer. 10 Therefore, the exploration on miRNAs in thyroid cancer is helpful for the identification of potential biological markers for thyroid cancer.…”

Section: Discussionmentioning

confidence: 99%

“…6 Through complementary binding to 3' untranslated regions (3′UTR), miRNAs exhibit suppressive impacts on gene expression. 6 The implication of miRNAs in cancers has been increasingly documented, 8,9 including in thyroid cancer. 6 The implication of miRNAs in cancers has been increasingly documented, 8,9 including in thyroid cancer.…”

Section: Introductionmentioning

confidence: 99%

“…7 Nowadays, miRNAs have gained a reputation as crucial factors in diverse biological activities, such as carcinogenesis, cell apoptosis, and proliferation. 6 The implication of miRNAs in cancers has been increasingly documented, 8,9 including in thyroid cancer. 10 miR-4319 has been recently illustrated to inhibit breast cancer and acute myeloid leukemia, 11,12 but its function and mechanism in thyroid cancer have never been investigated.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

miR‐4319 inhibited the development of thyroid cancer by modulating FUS‐stabilized SMURF1

Bian

2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Thyroid cancer, a common type of endocrine system cancer, has witnessed rising incidence and deaths over the past few years. The role of microRNAs is being increasingly discovered in a variety of cancers, including thyroid cancer. miR‐4319 has been elucidated in several studies to exert an antitumor function in multiple cancers but has never been explored in thyroid cancer. Our study proposed to explore the function and modulatory mechanism of miR‐4319 in thyroid cancer. First, we confirmed the downregulation of miR‐4319 in thyroid cancer tissues and cells, and revealed the correlation of miR‐4319 expression and clinical features in thyroid cancer. Functional assays illustrated that miR‐4319 attenuated proliferation, migration, and epithelial‐to‐mesenchymal transition (EMT) in thyroid cancer. Mechanistically, we identified through the miRDB database and proved that miR‐4319 targeted SMAD specific E3 ubiquitin protein ligase 1 (SMURF1). Furthermore, we discovered that miR‐4319 competed with fused in sarcoma (FUS) to bind to SMURF1, inhibiting the stabilization of SMURF1 messenger RNA. Rescue assays suggested that miR‐4319 retarded proliferation, migration, and EMT through SMURF1. Collectively, the results of this study showed that miR‐4319 inhibited the development of thyroid cancer by modulating FUS‐stabilized SMURF1, indicating miR‐4319 as a potent biological target for thyroid cancer.

show abstract

“…However, some studies have shown that increased levels of miRNA-885-5p in tissues or body fluids can be used as diagnostic markers for tumors and short survival period. [25][26]. Currently, studies involved in target genes of miRNA-885-5p are not enough.…”

Section: Validation Of Prognostic Values Of Mir-885-5p and Mtpn In Ccamentioning

confidence: 99%

ATO /miRNA-885-5p/MTPN axis induced reversal of drug-resistance in cholangiocarcinoma

Wang

Zhang

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

Backgroud: In recent years, the incidence of cholangiocarcinoma (CCA) has increased, and it has become the second most malignant tumor of the hepatobiliary system. Chemotherapy has become the main treatment for cholangiocarcinoma due to its difficulty in diagnosis and rapid progress. Primary drug resistance is the main reason for the poor efficacy of chemotherapeutic drugs. Methods Western blot and quantitative real-time PCR assays were used to detect the expression levels of myotrophin (MTPN) and microRNA-885-5p(miR-885-5p) in CCA tissues and cells; Cell viabilities treated with arsenic trioxide (ATO), 5-fluorouracil (5-Fu) and cisplatin (CDDP) were analyzed by a CCK-8 kit. Luciferase reporter assay detected the relationship between miR-885-5p and MTPN. Kaplan-Meier analysis showed survival time curve. Results We found that ATO can reduce the resistance of CCA cells to 5-Fu and CDDP and promote the killing effect of 5-Fu and CDDP. Low-dose ATO played an anti-drug-resistance role through up-regulating the expression of miR-885-5p. Combined with sequencing results and database prediction, we found that MTPN was a direct target gene of miR-885-5p. The sensitivity of CCA cells to 5-Fu and CDDP was increased after MTPN was knocked out. After MTPN knockout, the sensitivity of cholangiocarcinoma cells to 5-FU and CDDP was increased. ATO can reverse chemotherapy resistance induced by overexpression of MTPN. Conclusions Our study suggests that the ATO/miR-885-5p/MTPN axis is a potential therapeutic strategy for improving the sensitivity of CCA to chemotherapy.

show abstract

miR‑885‑5p suppresses osteosarcoma proliferation, migration and invasion through regulation of β‑catenin

Cited by 12 publications

References 25 publications

MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma

MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma

miR‐4319 inhibited the development of thyroid cancer by modulating FUS‐stabilized SMURF1

ATO /miRNA-885-5p/MTPN axis induced reversal of drug-resistance in cholangiocarcinoma

Contact Info

Product

Resources

About